Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Passage Bio Inc (NQ: PASG )

0.5500 +0.0140 (+2.61%)
Streaming Delayed Price Updated: 12:23 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 47,901
Open 0.5400
Bid (Size) 0.5394 (2)
Ask (Size) 0.5500 (10)
Prev. Close 0.5360
Today's Range 0.5200 - 0.5613
52wk Range 0.4510 - 1.790
Shares Outstanding 61,767,286
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
From Passage Bio
Via GlobeNewswire

Performance

YTD
-38.96%
-38.96%
1 Month
-6.94%
-6.94%
3 Month
-23.61%
-23.61%
6 Month
-54.92%
-54.92%
1 Year
-10.28%
-10.28%

More News

Read More
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
From Passage Bio
Via GlobeNewswire
Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)
From Passage Bio
Via GlobeNewswire
Passage Bio Welcomes Tom Kassberg to Board of Directors
From Passage Bio
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Passage Bio
Via GlobeNewswire
PASG Stock Earnings: Passage Bio Beats EPS for Q2 2024
Via InvestorPlace
Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
Passage Bio to Participate in Upcoming Investor Conferences
From Passage Bio
Via GlobeNewswire
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
From Passage Bio
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
From Passage Bio
Via GlobeNewswire
PASG Stock Earnings: Passage Bio Beats EPS for Q1 2024
Via InvestorPlace
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
From Passage Bio
Via GlobeNewswire
PASG Stock Earnings: Passage Bio Beats EPS for Q4 2023
Via InvestorPlace
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
Passage Bio to Participate in Upcoming Investor Conferences
From Passage Bio
Via GlobeNewswire
7 Analyst-Backed Stocks With Promising 10-Bagger Potential
Via InvestorPlace
Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Passage Bio
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.